The evaluation of omeprazole effect on the sensitivity of 99mTc-MDP bone-seeking to detect simulated closed fracture in the rat’s foot

Document Type : Original Article

Authors

1 School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran

3 Nuclear Medicine Department, Golestan General Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Introduction:Omeprazole (OP) is one the proton pump inhibitor (PPI) agents, and available over the counter in generic formulations. Epidemiological investigations have been confirmed a relationship between long term use of PPI agents and bone metabolism. Bone scintigraphy is commonly used for analysing the bone metabolism in clinical practice. This study was conducted to assess the effect of omeprazole on the sensitivity of bone imaging to distinguish simulated closed fracture in the rat’s foot.
Methods: A total number of 32 adult, male NMRI were chosen. The animals were divided into two principle groups equally for four and eight weeks experiment. Each group was equally divided into four groups. These subgroups included the standard or control rats (4W S and 8W S) not receiving omeprazole and the others that received 25 (4W OP 25 and 8W OP 25), 50 (4W OP 50 and 8W OP 50), 100 (4W OP 100 and 8W OP 100) mg/kg of the drug.  Reproducible closed fracture was created in the rat’s foot after 4 and 8 weeks of experiments. Radioisotope studies have been undertaken.
Results: All closed fractures created in the feet of animals were visualized by images. The radiotracer uptake ratio at affected foot (target) versus contralateral healthy foot (non-target) was not influenced by omeprazole in the different animal groups. The quantitative investigation indicated that biodistribution of radiotracer was not affected by omeprazole in the other parts of the skeleton.

Conclusion: Radioisotope imaging by 99mTc-MDP is sensitive modality to identify the occult fracture and is not affected by omeprazole.

Keywords

Main Subjects

References

  1. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ.. Radionuclide bone imaging: an illustrative review. Radiographics. 2003 Mar-Apr;23(2):341-58.
  2. Zuckier LS, Freeman LM.. Nonosseous, nonurologic uptake on bone scintigraphy: atlas and analysis. Semin Nucl Med. 2010 Jul;40(4):242-56.
  3. Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med. 2013 Apr;54(4):590-9.
  4. Marì C, Catafau A, Carriò I.. Bone scintigraphy and metabolic disorders. Q J Nucl Med. 1999 Sep;43(3):259-67.
  5. Even-Sapir E, Martin RH, Barnes DC, Pringle CR, Iles SE, Mitchell MJ. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology. 1993 Apr;187(1):193-8.
  6. Okamoto YM. Mechanism of accumulation of 99mTc-MDP to bone: correlation of in vivo data with in vitro data. Radiat Med. 1997 Jul-Aug;15(4):209-15.
  7. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001 Mar;45(1):27-37.
  8. Wellman HN, Schauwecker D, Robb JA, Khairi MR, Johnston CC. Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease. Clin Orthop Relat Res. 1977;(127):55-62.
  9. Pennington WT, Mott MP, Thometz JG, Sty JR, Metz D. Photopenic bone scan osteomyelitis: a clinical perspective. J Pediatr Orthop. 1999 Nov-Dec;19(6):695-8.
  10. Genant HK, Bautovich GJ, Singh M, Lathrop KA, Harper PV. Bone-seeking radionuclides: an in vivo study of factors affecting skeletal uptake. Radiology. 1974 Nov;113(2):373-82.
  11. Galasko CS. The pathological basis for skeletal scintigraphy. J Bone Joint Surg Br. 1975 Aug;57(3):353-9.
  12. Kanishi D. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol. 1993 Feb;75(2):239-46.
  13. Bernardo-Filho M, Santos-Filho SD, de Moura EG, Maiworm AI, de Camões Orlando MM, Penas ME, Cardoso VN, Bernardo LC, de Carvalho Brito L. Drug interaction with radiopharmaceuticals: a review. Braz Arch Biol Technol. 2005;48:13-27.
  14. Yu MD, Shaw SM. Potential interference of agents on radioiodide thyroid uptake in the euthyroid rat. J Nucl Med. 2003 May;44(5):832-8.
  15. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992 Jul;13(7):513-21.
  16. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994 Nov;35(11):1748-52.
  17. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med. 1994 Apr;21(4):348-56.
  18. Abu-Judeh HH, Naddaf SY, el-Zeftawy HA, Abdel-Dayem HM. G-CSF induced bone marrow hyperplasia: characteristic appearance on total body blood pool and delayed Tc-99m MDP bone scan. Clin Nucl Med. 1998 Jan;23(1):39-41.
  19. Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol. 1989 Dec;7(12):1800-6.
  20. Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology. 1999 Aug;59(2):57-77.
  21. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004 Aug;2(8):656-64.
  22. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006 Jun 24;367(9528):2086-100.
  23. Karam SM, Forte JG. Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. Am J Physiol. 1994 Apr;266(4 Pt 1):G745-58.
  24. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004 Jan;2(1):17-21.
  25. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53.
  26. Kirkpantur A, Altun B, Arici M, Turgan C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clin Pract. 2009 Feb;63(2):261-8.
  27. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010 May 10;170(9):765-71.
  28. Yang YX. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012 Dec;14(6):473-9.
  29. Merhige ME, Breen WJ, Shelton V, Houston T, D'Arcy BJ, Perna AF. Impact of myocardial perfusion imaging with PET and (82)Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. J Nucl Med. 2007 Jul;48(7):1069-76.
  30. Doroudi A, Erfani M, Norouzi B, Saadati SM, Kiasat A, Ahmadi F, Etesami B, Baghersad MH. Clinical application of ultrasound for preparation of (99m)Tc-sestamibi complex. Ann Nucl Med. 2015 Apr;29(3):295-301.
  31. Davidson RA, Wilcox CS. Newer tests for the diagnosis of renovascular disease. JAMA. 1992 Dec 16;268(23):3353-8.
  32. Ludwig V, Martin WH, Delbeke D. Calcium channel blockers: a potential cause of false-positive captopril renography. Clin Nucl Med. 2003 Feb;28(2):108-12.
  33. Böttcher M, Czernin J, Sun KT, Phelps ME, Schelbert HR. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med. 1995 Nov;36(11):2016-21.
  34. McDevitt GR Jr, Heironimus JD, Toney MO, Billingsley JL. Diffuse abdominal uptake of technetium-99m-methylene diphosphonate in a patient on continuous ambulatory dialysis during bone scintigraphy. J Nucl Med. 1992 Nov;33(11):2052-4.
  35. Kuno RC, Cerqueira MD. Enhanced bone metabolism induced by acupuncture. J Nucl Med. 1995 Dec;36(12):2246-7.
  36. Park CH, Kim HS, Shin HY, Kim HC. Hepatic uptake of Tc-99m MDP on bone scintigraphy from intravenous iron therapy (Blutal). Clin Nucl Med. 1997 Nov;22(11):762-4.
  37. Scott S, Alazraki N, Manaster B. Failure of bone scanning to detect fractures in a woman on chronic steroid therapy. Skeletal Radiol. 1984;12(3):204-7.
  38. Scott SM, Manaster BJ, Alazraki N, Wooten WW, Murphy K. Technetium-99m imaging of bone trauma: reduced sensitivity caused by hydrocortisone in rabbits. AJR Am J Roentgenol. 1987 Jun;148(6):1175-8.
  39. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev. 2008 Feb;66(2):103-8.
  40. Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009 Sep 20;64(1):9-13.
  41. Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJ, Annoni R, de Oliveira Penoni ÁC. Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop. 2015 Mar 14;50(2):232-8.
  42. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993 Jul;53(1):21-5.
  43. Yang YX. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf. 2008 Sep;3(3):204-9.

Files

Share

How to cite

Statistics